A DIAGNOSTIC TEST IDENTIFYING BENIGN LUNG NODULES WITHOUT BIOPSY
- It is estimated that there are tens of millions of patients in the total addressable global market.
- Current standard of care is an invasive lung biopsy, or watch-and-wait with multiple scans.
- SmartLung Dx is a non-invasive blood test that identifies lung nodules that are likely benign, enabling patients to avoid potentially risky invasive biopsy procedures.
- We believe this test will help minimize hospitalizations from lung biopsy complications.